home / stock / nbix / nbix articles
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...
H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differenti...
A substantial insider activity was disclosed on February 14, as GORMAN, Chief Executive Officer at Neurocrine Biosciences (NASDAQ:NBIX), reported t...
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX) released Phase 2 study results from two signal-seeking pipeline programs in...
Neurocrine Biosciences Inc (NASDAQ: NBIX) released topline data from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and ado...
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. ...
Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in ad...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH PR Newswire PDUFA Target Action Dates in Late December 2024 Highly Selective CRF 1 Antagonist is the Potent...
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 PR Newswire SAN DIEGO , June 3, 2024 /PRNewswire/ -- Neurocrine Bios...
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine PR Newswire - CAHtalyst™ Pediatr...